Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis

Lijun Wang, Heng Li, Xiaofei Gu, Zhen Wang, Su Liu, Liyong Chen*
Department of Anesthesiology, Daping Hospital, Third Military Medical University, Chongqing, China

Abstract

Background
Antiplatelet agents are commonly used for cardiovascular diseases, but their pleiotropic effects in critically ill patients are controversial. We therefore performed a meta-analysis of cohort studies to investigate the effect of antiplatelet therapy in the critically ill.

Methods
Nine cohort studies, retrieved from PubMed and Embase before November 2015, involving 14,612 critically ill patients and 4765 cases of antiplatelet users, were meta-analysed. The main outcome was hospital or 30-day mortality. Secondary outcome was acute respiratory distress syndrome (ARDS) or acute lung injury (ALI). Random- or fixed-effect models were taken for quantitative synthesis of the data.

Results
Antiplatelet therapy was associated with decreased mortality (odds ratio (OR) 0.61; 95% confidence interval (CI), 0.52–0.71; I² = 0%; P <0.001) and ARDS/ALI (OR 0.64; 95% CI, 0.50–0.82; I² = 0%; P <0.001). In every stratum of subgroups, similar findings on mortality reduction were consistently observed in critically ill patients.

Conclusions
Antiplatelet therapy is associated with reduced mortality and lower incidence of ARDS/ALI in critically ill patients, particularly those with predisposing conditions such as high-risk surgery, trauma, pneumonia, and sepsis. However, it remains unclear whether similar findings can be observed in the unselected and broad population with critical illness.

Introduction
Sepsis and acute respiratory distress syndrome (ARDS) in the United States both contribute significantly to the expanding burden of critical illness. The incidence rate of sepsis or septic
shock appears to be increasing [1], and with an annual cost of $17 billion, the mortality is reported at approximately 30% in sepsis [2]. Meanwhile, epidemiologic evidences suggest an incidence of 190,600 patients annually for ARDS and the mortality is presently estimated at 25–38% [3–4]. Importantly, sepsis and multiple organ failure (MOF) are leading causes of death in the critically ill. However, among several factors associated with MOF, ARDS, and sepsis, platelet activation and sequestration may play one of the most important roles in microvascular thrombosis and releasing of inflammatory mediators through platelet–endothelial interaction [5–7]. Moreover, a decline in circulating platelet count can be commonly observed in critically ill patients, and thrombocytopenia is a powerful predictor of mortality [8–10]. Given these reasons, beneficial effect of impeding platelet activation has been hypothesized for critically ill patients.

Antiplatelet agents are used to reduce platelet activation and their cardiovascular benefits in patients with the risk of heart disease, stroke, and peripheral arterial thrombosis are widely accepted in clinical practice. However, their pleiotropic effects in critically ill patients yielded controversial results. Many observational studies have demonstrated a protective effect of antiplatelet agents in critically ill patients [11–13], but some are not [14–15]. More unfortunately, no proper reports exploring the therapeutic effects of antiplatelet agents in randomized controlled studies had been previously published; therefore, we may not definitely know whether antiplatelet agents have beneficial effects, or whether these findings were observed owing to the bias effect.

Up to now, no syntheses of the evidence have been published to recapitulate and summarize the affect of this therapy in ICU population. Consequently, we conducted this meta-analysis to pool the available data and to explore the possible impact of anti-platelet agents on ARDS/ALI and risk of mortality in critically ill patients.

Methods

This meta-analysis was performed in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [16]. Neither ethical approval nor patient consent was required because this is a meta-analysis on base of previously published studies.

Search Strategy

Without language restrictions, electronic databases including Pubmed, Embase were retrieved to identify relevant studies from inception to November 10, 2015. A combination of exploded Medical Subject Headings (MESH) terms and corresponding keywords was used while searching. The search terms were as follows: ('platelet aggregation inhibitor', 'antiplatelet', 'anti-platelet', 'platelet inhibitor', 'aspirin', 'acetyl salicylic acid', 'clopidogrel') and ('ARDS', 'acute respiratory distress syndrome', 'ALI', 'acute lung injury', 'acute respiratory failure'). Additionally, We hand-searched the reference lists of each selected study, as well as previous review articles to obtain other potential relevant articles.

Inclusion Criteria

Published cohort studies meeting the following criteria were included: (1) population: critically ill patients, or rather, it referred to ICU or emergency patients with ARDS/ALI predisposing conditions, such as sepsis, septic shock, transfusion, pancreatitis, pneumonia, trauma, aspiration, or high-risk surgery; (2) comparison intervention: with and without anti-platelet therapy; (3) one or more the following outcomes: newly developed ARDS/ALI, hospital or 30-day mortality. In the case of duplicate publication, we only included studies that were the most informative and complete.
Data Extraction and Quality Assessment

Two investigators (W. L. J. and L. H.) independently screened the abstracts or titles of the studies from the electronic search to identify all potential eligible studies and extracted data. Discrepancies were resolved by consensus or a third reviewer (G. X. F.). The following data were recorded: first author, publication year, country, study design, sample size, outcomes of the studies, and definition of anti-platelet therapy. We pooled the short-term mortality (hospital or 30-day mortality) and new development of ARDS/ALI with the adjusted data. We also checked the supplementary files and contacted the authors for available information where necessary.

The study level risk of bias was evaluated using the nine-star Newcastle-Ottawa Scale (NOS) [17], which consists of three major aspects: selection, comparability, and outcome. And we judged studies with a score of nine or eight stars to be at low risk of bias, seven or six stars to be at medium risk, and below six to be at high risk of bias.

Statistical Analysis

All statistical analyses were performed using STATA, version 12.0 (Stata Corporation, College Station, Texas). A summary odds ratio (OR) was obtained on base of the adjusted OR in all analyses involved in this report. The hazard ratio (HR) and risk ratio (RR) were regarded as the eligible OR directly because all provided effect sizes of similar magnitude [18]. To calculate the adjusted OR with the 95% CI, a fixed-effects model was taken when significant heterogeneity was not present (the Q statistic ($p > 0.1$), $I^2 < 50\%$). Elsewise, a random-effects model was used. We likewise performed predefined subgroup analyses to study the effect of antiplatelet therapy in critically ill patients. To assess the effect of a single study on pooled estimate, a sensitivity analysis was used by omitting one study in turn. Funnel plots and Egger’s linear regression tests were taken to evaluate publication bias [19]. A $P$ value less than 0.05 was considered to indicate statistical significance.

Results

Study Selection and Study Characteristics

Fig 1 shows the detailed procedure of our literature search and selection. Our initial query yielded 1464 potentially relevant publications, of which 83 were excluded for duplicate studies and 1350 studies were excluded according to the titles and abstracts. After reviewing the full text of the remaining 31 studies, we identified 9 cohort studies in this present meta-analysis [14–15,20–26]. Of twenty-two full-text reports that were excluded, one [27] did not provide sufficient data to calculate the risk estimates. One report [28] was excluded because it was a duplicate study. Four [12,29–31] were excluded because they were unrelated. In addition, eleven reviews or editorial articles and five animal studies were likewise excluded.

The main characteristics of the nine selected cohort studies in this meta-analysis are shown in Table 1. In total, 14,612 patients (including 4765 cases of antiplatelet users) were enrolled in our meta-analysis. The main outcome of hospital or 30-day mortality was reported in six of nine articles [14–15,20–21,24,26]. Four of nine studies reported ARDS/ALI [15,22,23,25]. Four were prospective studies [15,22,24,26], and the residual were retrospective studies [14,20,21,23,25]. Only one study was population based. There was a congruous definition of ARDS/ALI between involved studies [32], but definitions of anti-platelet therapy included in the studies were not the same. The quality of the studies included was assessed by NOS scores, and the average NOS score of the involved studies was 6.9 (the range was 6 to 7). The detail is described in SI File.
Meta-Analysis of Outcomes

Figs 2 and 3 show the pooled results from the fixed-effects model combining the adjusted ORs for hospital or 30-day mortality and ARDS/ALI, respectively. On base of a meta-analysis of with six reports, antiplatelet therapy was associated with a decreased risk of hospital or 30-day mortality (OR 0.61, (95% CI, 0.52 to 0.71); \( P < 0.001 \)), with very low between-study heterogeneity (\( I^2 = 0\%; P = 0.738 \)). We also carried out a meta-analysis of the incidence rate of newly developed ARDS/ALI with four studies. Similarly, the pooled results indicated that antiplatelet therapy had a beneficial impact on reducing ARDS/ALI (OR 0.64, (95% CI, 0.50 to 0.82); \( P < 0.001 \)). There also was very low heterogeneity among the studies (\( I^2 = 0\%; P = 0.539 \)).

Subgroup and Sensitivity Analyses

To study the possibly existed heterogeneity, we performed a prespecified subgroup analysis according to predisposing conditions (sepsis/septic shock or > predisposing conditions), adjusted by propensity score (yes or no), type of mortality (hospital mortality or 30-day mortality), type of effect size (OR or HR), antiplatelet agents exposure (current exposure or former exposure), aspirin for antiplatelet therapy only (yes or no), and sample size (\( \leq 1000 \) or >1000). Our subgroup analyses suggested the effect of anti-platelet therapy on decreasing the incidence rate of mortality in ICU population with critical illness was consistent. Details can be shown in File. In addition, sensitivity analyses suggested the overall combined OR didn’t materially alter by exclusion of any single study, with a range from 0.59 (95% CI, 0.50–0.70) to 0.63 (95% CI, 0.53–0.73).
Publication Bias

The possibility of publication bias was judged by funnel plots and Egger's test. There was no evidence of publication bias based on the funnels plot (Fig 4) and Egger’s test (mortality, $P = 0.891$; ARDS/ALI, $P = 0.146$). However, the low power with only six studies for mortality and four studies for ARDS/ALI confined the interpretability.

Discussion

Key Findings

The principal finding of our analysis is that antiplatelet therapy is associated with decrease in ARDS/ALI and mortality. To the best of our knowledge, this is the first meta-analysis to explore the effects of anti-platelet treatment on the risk of ARDS/ALI and mortality in critically ill patients with high-quality cohort study and adjusted data. Additionally, the beneficial effect of anti-platelet treatment on mortality was likewise present in every stratum from subgroup analyses. All this may suggest that the “pleiotropic effects” of anti-platelet therapy probably will be a novel therapeutic approach in critically ill patients in the future.

Table 1. Main characteristics of cohort studies included in this meta-analysis.

| Study/Year     | Country   | No. total (Anti/Nonanti) | Study population                          | Study design | Main outcomes                          | Definition of antiplatelet therapy                                                                 | Study quality* |
|----------------|-----------|--------------------------|-------------------------------------------|--------------|----------------------------------------|--------------------------------------------------------------------------------------------------|----------------|
| Valerio-Rojas, 2013 [14] | USA       | 651(272/379)             | Adult ICU patients with severe sepsis and septic shock | SRC          | Hospital mortality, ICU mortality, ARDS/ALI | Using ASA, clopidogrel, ticlopidine, dipyridamole at the time of ICU admission                     | 7              |
| Erlich, 2011 [23]               | USA       | 161(79/82)               | Adult ICU patients with >1 predisposing ALI condition | PRC          | ARDS/ALI, hospital mortality, ICU mortality | Using ASA, clopidogrel bisulfate, ticlopidine hydrochloride, cilostazol, dipyramidole, anagrelide, persantine at the time of hospital admission | 7              |
| Mazzelfi, 2015 [25]            | USA       | 375(181/194)             | Adult patients with aortic valve replacement surgery | SRC          | ARDS                                   | Taking aspirin within 5 days of surgery                                                              | 7              |
| Otto, 2013 [20]                | Germany   | 886(187/699)             | Adult ICU patients with severe sepsis or septic shock | SRC          | Hospital mortality, ICU mortality         | Taking ASA or clopidogrel during the ICU stay,a dose of 100mg/d ASA and 75mg/d clopidogrel or either of the anti-platelet drugs | 7              |
| Eisen, 2012 [21]               | Australia | 5523(2082/3441)          | ICU patients with SIRS or sepsis           | SRC          | Hospital mortality, renal injury         | Defined as ASA use for the 24-hr period around the time of SIRS recognition                        | 7              |
| Chalmers, 2008 [24]            | UK        | 1007(311/696)            | ED patients with community-acquired pneumonia | SPC          | 30-day mortality                        | Using aspirin on admission                                                                            | 6              |
| Falcone, 2015 [26]             | Italy     | 1005(390/615)            | Adult ED patients with community-acquired pneumonia | SPC          | 30-day mortality                        | Using aspirin before and during hospitalization                                                         | 7              |
| Kor, 2011 [22]                 | USA       | 3855(976/2879)           | Adult ED patients with >1 predisposing ARDS condition | MPC          | ARDS, hospital mortality, ICU mortality   | Defined as aspirin therapy pre-hospitalization                                                        | 7              |
| Chen, 2015 [15]                | USA       | 1149(287/862)            | Adult ICU patients with high risk for ARDS  | SPC          | ARDS/ALI, hospital mortality             | Using aspirin before hospital admission                                                              | 7              |

Anti/Nonanti antiplatelet/nonantiplatelet, ICU intensive care unit, ARDS acute respiratory distress syndrome, ALI acute lung injury, SPC single-centre prospective cohort, SRC single-centre retrospective cohort, MPC multi-centre prospective cohort, PRC population-based retrospective cohort, Study quality* assessed by Newcastle-Ottawa Scale, ASA aspirin

doi:10.1371/journal.pone.0154754.t001
Possible Mechanism

Although antiplatelet treatment may decrease the risk of mortality and ARDS/ALI in critically ill patients, the reason remains unclear and can be explained by several potential mechanisms. First, activated platelets may contribute to micro-vascular thrombosis and organ failure. Antiplatelet therapy can impede platelet activation and the surface expression of adhesion molecules, a pivotal process in microvascular thrombus formation [33]. This viewpoint is proved by an animal study, in which platelet aggregation inhibitors abolished lipopolysaccharide (LPS)-induced thrombocytopenia and decreased fibrin deposition within the pulmonary microcirculation [34]. Nevertheless, the mortality rates in critically ill patients did not appear to be substantially influenced by heparin in two previously published meta-analyses [35–36]. Similarly, neither anti-thrombin III therapy nor tissue factor pathway inhibitor revealed a beneficial effect on survival [37–38]. Therefore, the anti-thrombosis function may be not the only
possible mechanism of the benefit of anti-platelet treatment in critically ill patients. Second, antiplatelet agents also manifestly affect inflammatory processes and immune responses. Platelets can modulate inflammatory responses through: (1) releasing of pro- or anti-inflammatory compounds such as cytokines, chemokines; (2) releasing of antibacterial compounds and, together with neutrophils, trapping of bacteria; (3) mediating complement activation; (4) neutrophil-, macrophage- and endotheliocyte-mediated adhesion leading to alterations of cellular functions such as production of reactive oxygen species (ROS), cytokines, and chemokines as well as recruitment and immigration of leukocytes at the site of tissue damage [39]. Platelet activation also reveals a significant impact on the innate immune response through pathogen recognition by toll-like receptors (TLRs) and the expression of cell surface receptors [40]. And in an animal model of sepsis, anti-inflammatory agents have greatly shown a beneficial effect on mortality [41]. However, previous published randomized studies described a consistent result of no survival benefit of ibuprofen in sepsis [42–43]. Third, platelet activation also plays an important role in the pathobiology of disease processes. In the pathogenesis of ARDS, for instance, both an uncontrolled inflammatory response and dys-regulated coagulation are key pathways [44]. ARDS is largely predicated on the key roles for platelets in these two pathways. At sites of lung injury, platelets activation act as signalling molecules to propagate an immune response, promoting the recruitment of neutrophils to the damaged alveolus [45]. Besides, delayed neutrophil apoptosis is a remarkable feature of ARDS, allowing inflammatory cells to remain within the alveolar space, prolonging the period of lung injury and hypoxia [46]. An experimental study indicates that aspirin-triggered production of the anti-inflammatory lipid mediator 15-epi-lipoxin A4 restores neutrophil apoptosis and promotes the resolution of alveolar inflammation [47]. Further research is needed to determine whether the effect of anti-platelet treatment on improving patient outcomes is mediated via their microcirculatory improvement and/or anti-inflammatory effects, or others.

Clinical Implications

Despite advancements into the pathophysiology of critically ill patients, no specific or reliable intervention has currently been developed [48–49]. Ascertaining a cost-effective and safe agent would represent a significant promotion in treating this deadly and costly condition, even if the benefit was low or adjuvant. Our findings suggested antiplatelet therapy might show a
protective effect on decreasing the incidence rate of short-term mortality and ARDS/ALI. Accordingly, it may act as a prophylactic agent and/or as a treatment in critically ill patients, such as sepsis, ALI, and ARDS. Importantly, with a large number of the critically ill population, even a low rate of avoidable harm will be associated with massive preventable deaths. Consequently, it is imperative to identify the role of antiplatelet treatment as an adjunctive therapy in critically ill patients. In addition, in order to know the influence of exposure timing (former, current use) of antiplatelets on mortality in critically ill patients, we carried out a special subgroup analysis between current and former antiplatelet agent users. There were no obvious differences after comparison in these groups; however, current antiplatelet agent use revealed a stronger effect on survival benefits.

Strengths and Weaknesses

The strength of this study is that there was an exhaustive search without language restrictions and PRISMA guidelines was used as our systematic review methods. Meanwhile, studies were assessed strictly for methodological quality, and only those of high quality were involved in our analysis. In addition, no significant heterogeneity between the included studies was observed in this study. However, our meta-analysis knows several limitations, the principal one being lack of randomized trials. Although more and more evidence emphasizes the potential benefit of antiplatelet therapy in critically ill patients, none of the randomized trials came out to report the relationship between the two described above. Considering the characteristics of observational study, we should acknowledge selection bias and potential confounding. Actually, just like any observational study, it remains impossible to entirely exclude confounding, especially when the observed association is weak to some extent. Second, the definition of intensive care patients was wide and imprecise. In this study, critically ill patients was defined as the population with ALI/ARDS predisposing risk factors, involving sepsis, pancreatitis, transfusion, pneumonia, aspiration, trauma, or high-risk surgery. Nevertheless, it remains unclear whether the conclusion was fit for the unselected and broad population with critical illness. Third, different definition of antiplatelet therapy in the included studies was used, and this may have a potential influence on our conclusion. Finally, unpublished studies or conference abstracts were not included. However, although publish bias was not found in our meta-analysis, unpublished studies or conference abstracts might be of great importance.

Conclusions

In aggregate, our meta-analysis suggests that antiplatelet therapy is associated with decreased mortality, as well as a decreased incidence rate of ARDS/ALI in the critically ill, especially those with one or more predisposing risk factors such as high-risk surgery, trauma, pneumonia, and sepsis. However, it is also unknown whether similar results can be found in the unselected and broad population with critical illness. There is, thus, a great need for well de-signed, high-quality, large, randomized trials to confirm the effect of antiplatelet therapy in critically ill patients.

Supporting Information

S1 File. Quality assessment with Newcastle-Ottawa Scales.
(DOC)

S2 File. Subgroup analyses for mortality.
(DOC)
Acknowledgments

This work was supported by a grant from the National Natural Science Foundation of China (81071588).

Author Contributions

Conceived and designed the experiments: LW HL XG ZW SL LC. Performed the experiments: LW HL XG. Analyzed the data: LW ZW SL. Contributed reagents/materials/analysis tools: LC. Wrote the paper: LW LC.

References

1. Stoller J, Halpin L, Weis M, Aplin B, Qu W, Georgescu C, et al. Epidemiology of severe sepsis: 2008–2012. J Crit Care. 2016; 31: 58–62. doi: 10.1016/j.jcrc.2015.09.034 PMID: 26601855
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29: 1303–10. PMID: 11445675
3. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005; 353: 1685–93. PMID: 16236739
4. McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014; 371: 1695–703. doi: 10.1056/NEJMoa1403285 PMID: 25268516
5. Yadav H, Kor DJ. Platelets in the pathogenesis of acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2015; 309: L915–L923. doi: 10.1152/ajplung.00266.2015 PMID: 26320157
6. Katz JN, Kolappa KP, Becker RC. Beyond thrombosis: the versatile platelet in critical illness. Chest. 2011; 139: 658–668. doi: 10.1378/chest.10-1971 PMID: 21362652
7. Semple JW, Italiano JJ, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011; 11: 264–274. doi: 10.1038/nri2956 PMID: 21436837
8. Vandijck DM, Blot SI, De Waele JJ, Hoste EA, Vandewoude KH, Decruyenaere JM. Thrombocytopenia and outcome in critically ill patients with bloodstream infection. Heart Lung. 2010; 39: 21–26. doi: 10.1016/j.hrtlng.2009.07.005 PMID: 20109983
9. Wu Q, Ren J, Wang G, Li G, Anjum N, Hu D, et al. Effect of Persistent Thrombocytopenia on Mortality in Surgical Critical Care Patients: A Retrospective Study. Clin Appl Thromb Hemost. 2015.
10. Moreau D, Timsit JF, Vesin A, Garroutte-Orgeas M, de Lassence A, Zahar JR, et al. Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. Chest. 2007; 131: 1735–1741. PMID: 17475637
11. Tsai MJ, Ou SM, Shih CJ, Chao PW, Wang LF, Shih YN, et al. Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. Intensive Care Med. 2015; 41: 806–813. doi: 10.1007/s00134-015-3760-y PMID: 25829229
12. Boyle AJ, Di Gangi S, Hamid UI, Mottram LJ, McNamee L, White G, et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care. 2015; 19: 109. doi: 10.1186/s13054-015-0846-4 PMID: 25887566
13. Winning J, Neumann J, Kohl M, Claus RA, Reinhart K, Bauer M, et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med. 2013; 38: 32–37. doi: 10.1097/CCM.0b013e3181b4275c PMID: 19770746
14. Valero-Rojas JC, Jaffer IJ, Kor DJ, Gajic O, Cartin-Ceba R. Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract. 2013; 2013: 782573. doi: 10.1155/2013/782573 PMID: 23909620
15. Chen W, Janz DR, Bastarache JA, May AK, O'Neal HJ, Bernard GR, et al. Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. Crit Care Med. 2015; 43: 801–807. doi: 10.1097/CCM.0000000000000789 PMID: 25559436

16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264–269, W64. PMID: 19622511

17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603–605. doi: 10.1007/s10654-010-9491-2 PMID: 20652370

18. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ. 1998; 316: 989–991. PMID: 9550961

19. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BJM. 1997; 315: 629–634. PMID: 9310563

20. Otto GP, Sossdorf M, Boettel J, Kabisch B, Breuel H, Winning J, et al. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets. 2013; 24: 480–485. doi: 10.3109/09537104.2012.724482 PMID: 22994591

21. Eisen DP, Reid D, McBryde ES. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med. 2012; 40: 1761–1767. doi: 10.1097/CCM.0b013e318246b9df PMID: 22610182

22. Kor DJ, Ehrlich J, Gong MN, Malinchoc M, Carter RE, Gajic O, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med. 2011; 39: 2393–2400. doi: 10.1097/CCM.0b013e318225757f PMID: 21725238

23. Ehrlich JM, Talmor DS, Carlin-Ceba R, Gajic O, Kor DJ. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest. 2011; 139: 289–295. doi: 10.1378/chest.10-0891 PMID: 20688925

24. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 2008; 121: 1002–1007. doi: 10.1016/j.ajmed.2008.06.030 PMID: 18954848

25. Mazzzelli M, Kassa W, Gammie J, Tanaka K, Roman P, Zhan M, et al. Preoperative Aspirin Use and Lung Injury After Aortic Valve Replacement Surgery: A Retrospective Cohort Study. Anesth Analg. 2015; 121: 271–277. doi: 10.1213/ANE.0000000000000793 PMID: 25993389

26. Falcone M, Russo A, Cangemi R, Farcomeni A, Calvieri C, Barilla F, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc. 2015; 4: e1595.

27. Harr JN, Moore EE, Johnson J, Chin TL, Wohlauer MV, Maier R, et al. Antiplatelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients. Crit Care Med. 2013; 41: 399–404. doi: 10.1097/CCM.0b013e31826ab38b PMID: 23263579

28. O'Neal HJ, Koyama T, Koehler EA, Siew E, Curtis BR, Fremont RD, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med. 2011; 39: 1343–1350. doi: 10.1097/CCM.0b013e3182120992 PMID: 21336116

29. Gross AK, Dunn SP, Feola DJ, Martin CA, Chamigo R, Li Z, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis. 2013; 35: 147–154. doi: 10.1007/s11239-012-0833-4 PMID: 23124575

30. Kor DJ, Talmor DS, Banner-Goodspeed VM, Carter RE, Hinds R, Park PK, et al. Lung Injury Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open. 2012; 2.

31. Ahmed AH, Litell JM, Malinchoc M, Kashyap R, Schiller HJ, Pannu SR, et al. The role of potentially preventable hospital exposures in the development of acute respiratory distress syndrome: a population-based study. Crit Care Med. 2014; 42: 31–39. doi: 10.1097/CCM.0b013e318298a6db PMID: 23982022

32. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149: 816–824. PMID: 7509706

33. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med. 2010; 38: S35–S42. doi: 10.1097/CCM.0b013e3181c9e31d PMID: 2008912
34. Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets. 2009; 20: 50–57. doi: 10.1080/0953710802503368 PMID: 19172522

35. Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013; 41: 2088–2098. doi: 10.1097/CCM.0b013e31828c104 PMID: 23782973

36. Zarychanski R, Abou-Setta AM, Turgeon AF, Kumar A, Houston DS, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015; 43: 511–518. doi: 10.1097/CCM.0000000000000763 PMID: 25493972

37. Afshari A, Wetterslev J, Moller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ. 2007; 335: 1248–1251. PMID: 18037615

38. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290: 238–247. PMID: 12851279

39. Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015; 114: 449–458. doi: 10.1160/TH14-12-1067 PMID: 26293514

40. Semple JW, Mantell BJ, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011; 11: 264–274. doi: 10.1038/nri2956 PMID: 21436837

41. Aronoff DM. Cyclooxygenase inhibition in sepsis: is there life after death? Mediators Inflamm. 2012; 2012: 696897. doi: 10.1155/2012/696897 PMID: 22665954

42. Arons MM, Wheeler AP, Bernard GR, Christman BW, Russell JA, Schein R, et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med. 1999; 27: 699–707. PMID: 10321658

43. Bernard GR, Wheeler AP, Russell JA, Sumner WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997; 336: 912–918. PMID: 9070471

44. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014; 306: L217–L230. doi: 10.1152/ajlpc.00311.2013 PMID: 24318116

45. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006; 116: 3211–3219. PMID: 17143330

46. Matute-Bello G, Liles WC, Radella FN, Steinberg KP, Ruzinski JT, Jonas M, et al. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997; 156: 1969–1977. PMID: 9412582

47. El KD, Jozsef L, Pan W, Wang L, Petasis NA, Serhan CN, et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med. 2008; 180: 311–319. doi: 10.1164/rcrm.200810-1601OC PMID: 19483113

48. Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pfeifer K, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014; 370: 1683–1693. doi: 10.1056/NEJMoa1401602 PMID: 24635773

49. Boyle AJ, McNamee JJ, McAuley DF. Biological therapies in the acute respiratory distress syndrome. Expert Opin Biol Ther. 2014; 14: 969–981. doi: 10.1517/14712598.2014.905536 PMID: 24702248